This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (3) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cesarone, M. R. Articles by Corsi, M. Search for Related Content PubMed PubMed Citation Articles by Cesarone, M. R. Articles by Corsi, M. Social Bookmarking                         What's this?

Improvement of Diabetic Microangiopathy With Pycnogenol®: A Prospective, Controlled Study

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G D'Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L'Aquila University, Italy; Institute Pharmaceutical Chemistry, Westfälische Wilhelms-Universität Münster, Germany

G. Belcaro, MD, PhD

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G D'Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L'Aquila University, Italy; Institute Pharmaceutical Chemistry, Westfälische Wilhelms-Universität Münster, Germany; AP/PEA Project, C.SO Umberto I, 18, San Valentino, PE, Italy; Cardres{at}aol.it

P. Rohdewald, PhD

L. Pellegrini, MD

A. Ledda, MD

G. Vinciguerra, PhD

A. Ricci, MD

G. Gizzi, MD

E. Ippolito, MD

F. Fano

M. Dugall, MD

G. Cipollone, MD

G. Acerbi, MD

M. Cacchio, MD

G. Del Boccio, MD

A. Di Renzo

S. Stuard, MD

M. Corsi, MD

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G D'Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L'Aquila University, Italy; Institute Pharmaceutical Chemistry, Westfälische Wilhelms-Universität Mänster, Germany

The aim of this study was to investigate the clinical efficacy of oral Pycnogenol^® (Horphag Research Ltd, United Kingdom) in patients with diabetic microangiopathy. Patients without a history of diabetic ulcerations were treated with Pycnogenol. Patients received oral Pycnogenol (50 mg capsules, 3 times daily for a total of 150 mg daily for 4 weeks). A group of 30 patients was included (severe microangiopathy); 30 comparable patients were observed as controls (no treatment during the observation period). All patients (age, 59 years; range, 55-68 years; male:female = 18:12) included in the treatment group completed the 4-week study. Also, all controls completed the follow-up period. There were no drop-outs. All included subjects had signs and symptoms of diabetic microangiopathy. The duration of diabetes—from the first signs/symptoms—was on average 7.5 years (SD = 3). After 4 weeks, microcirculatory and clinical evaluations showed a progressive decrease in skin flux at rest in the foot (indicating an improvement in the level of microangiopathy), a significant decrease in capillary filtration, and a significant improvement in the venoarteriolar response in all treated subjects. There were no visible effects in controls except a slight reduction in skin flux at rest in the foot. Treatment was well tolerated in both groups. In conclusion, this study confirms the clinical efficacy of Pycnogenol in patients with diabetic microangiopathy. The study indicates the clinical role of Pycnogenol in the management, treatment, and control of this common clinical problem. The treatment may be also useful to prevent diabetic ulcerations by controlling the level of microangiopathy.

Angiology, Vol. 57, No. 4, 431-436 (2006)
DOI: 10.1177/0003319706290318


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?